Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Tryp Therapeutics Inc (TRYP.CN)

Tryp Therapeutics Inc (TRYP.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 5,785
  • Shares Outstanding, K 96,419
  • Annual Sales, $ 0 K
  • Annual Income, $ -5,267 K
  • 60-Month Beta -1.60
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade TRYP.CN with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.04
  • Most Recent Earnings $-0.01 on N/A
  • Latest Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0250 +140.00%
on 04/10/24
0.0650 -7.69%
on 04/26/24
+0.0350 (+140.00%)
since 04/01/24
3-Month
0.0100 +500.00%
on 03/05/24
0.0650 -7.69%
on 04/26/24
+0.0200 (+50.00%)
since 02/01/24
52-Week
0.0100 +500.00%
on 03/05/24
0.1100 -45.45%
on 09/11/23
-0.0300 (-33.33%)
since 05/01/23

Most Recent Stories

More News
Markets Head into Christmas with Sparse Economic Lineup

Monday U.S. Economic Lookahead NAHB Home Builders Index (Dec.) Featured Earnings HEICO ...

HEI : 208.07 (+0.32%)
CCL : 14.47 (-2.36%)
SCS : 12.03 (unch)
NKE : 90.34 (-2.08%)
GIS : 69.99 (-0.67%)
FDX : 260.73 (-0.40%)
MU : 109.70 (-2.89%)
CTAS : 663.59 (+0.80%)
TTC : 87.23 (-0.41%)
PAYX : 119.41 (+0.51%)
KMX : 67.21 (-1.12%)
AVO : 11.56 (+1.85%)
Sen. Cory Booker Pushing for Psychedelics Treatment of Mental Health

The psychedelic story is coming back strong. All after Sen. Cory Booker tweeted, “Massive breakthroughs in medical studies with psilocybin and MDMA are showing strong promise for patients with PTSD,...

CYBN : 0.3500 (unch)
TRYP.CN : 0.0600 (unch)
TRYPF : 0.0562 (+32.24%)
FTHW.VN : 0.055 (-8.33%)
FTHWF : 0.0412 (-8.44%)
CMPS : 8.48 (-1.05%)
SILO.CN : 0.0100 (unch)
SILFF : 0.0112 (+53.42%)
Stocks in play: Tryp Therapeutics Inc

Today announced the filing of two new provisional patent applications. One patent application, #63/405,786, ...

TRYP.CN : 0.0600 (unch)
TRYP THERAPEUTICS INC. ANNOUNCES CLOSING OF THIRD TRANCHE OF PRIVATE PLACEMENT

/CNW/ -- Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company focused on developing psilocybin-based...

TRYP.CN : 0.0600 (unch)
TRYPF : 0.0562 (+32.24%)
Stocks in play: Tryp Therapeutics Inc

Announced a non-brokered private placement to its co-Founder and Executive Director, William J. Garner, ...

TRYP.CN : 0.0600 (unch)
Stocks in play: Tryp Therapeutics Inc

Announced today that it has received confirmation from the U.S. Food and Drug Administration that its ...

TRYP.CN : 0.0600 (unch)
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Set to Proceed with its Phase 2a Fibromyalgia Study Following FDA Confirmation

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) just announced that it would be proceeding with its upcoming Phase 2a fibromyalgia study, following a confirmation from the U.S. Food and Drug Administration...

TRYP.CN : 0.0600 (unch)
TRYPF : 0.0562 (+32.24%)
BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Clinical Trials, Focus Puts It ‘In Pretty Rarefied Air’

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF)  is advancing toward the launch of four phase 2a studies of its two novel drug candidates, TRP-8802 and TRP-8803, for treating fibromyalgia, phantom limb pain,...

TRYP.CN : 0.0600 (unch)
TRYPF : 0.0562 (+32.24%)
Atai Life Sciences (NASDAQ: ATAI) Increases Stake in Psychedelic Start-Up Compass Pathways

Atai Life Sciences (NASDAQ: ATAI) , a clinical-stage biopharmaceutical company whose objective is to transform how mental health conditions are treated, has increased its stake in Compass Pathways. Compass...

ATAI : 2.0500 (+3.54%)
CMPS : 8.48 (-1.05%)
TRYP.CN : 0.0600 (unch)
TRYPF : 0.0562 (+32.24%)
FDA green lights Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Psychedelic Drug Trial for Treating Fibromyalgia, After Completing IND Process

Psychedelic drug medical research firm Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) has received final U.S. Food and Drug Administration (“FDA”) approval to get under way with its planned clinical...

TRYP.CN : 0.0600 (unch)
TRYPF : 0.0562 (+32.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Tryp Therapeutics Inc is a clinical-stage biotechnology company focused on developing psilocybin-related molecules, for the treatment of diseases with unmet medical needs. Tryp's program is focused on the development of synthetic psilocybin-related molecules as a new class of drug for the treatment of...

See More

Key Turning Points

3rd Resistance Point 0.0600
2nd Resistance Point 0.0600
1st Resistance Point 0.0600
Last Price 0.0600
1st Support Level 0.0600
2nd Support Level 0.0600
3rd Support Level 0.0600

See More

52-Week High 0.1100
Fibonacci 61.8% 0.0718
Fibonacci 50% 0.0600
Last Price 0.0600
Fibonacci 38.2% 0.0482
52-Week Low 0.0100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar